Abstract
Larotrectinib (VITRAKVI((R))) is an orally administered, small molecule, highly-selective, tropomyosin receptor kinase (TRK) inhibitor that was develo......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
